ArticleExperimental and therapeutic medicine2026
Sequential fulminant hepatitis and toxic epidermal necrolysis induced by tislelizumab: A case report.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs)-monoclonal antibodies that block inhibitory pathways such as programmed cell death protein 1 (PD-1)/PD-1 ligand to restore T-cell antitumor activity-are increasingly used in advanced non-small cell lung cancer. These agents are associated with severe multisystem immune-related adverse events (irAEs). The present study reported the first case of sequential grade 4 hepatotoxicity and toxic epidermal necrolysis (TEN) induced by the anti-PD-1 antibody tislelizumab. A 70-year-old female patient with advanced lung squamous cell carcinoma developed acute severe mixed liver injury (alanine aminotransferase, 1,741.6 U/l) followed by extensive TEN shortly after initiation of tislelizumab combined with chemotherapy. The toxicities were refractory to conventional hepatoprotective and antihistamine therapies but responded to high-dose corticosteroids combined with intravenous immunoglobulin (IVIG), leading to full recovery. This case highlights that PD-1 inhibitors can induce rare yet life-threatening overlapping irAEs. Clinicians should maintain heightened vigilance for such severe toxicities, particularly in elderly patients receiving combination immunotherapy, and promptly initiate multidisciplinary management including corticosteroids and IVIG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.